Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | XIAP | P98170 | 8/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20260345 | 0.87 | MMP1 (0.44) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL26497803 | 0.85 | MMP1 (0.43) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL14222801 | 0.85 | MMP1 (0.43) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL10154768 | 0.85 | MMP1 (0.43) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL11928050 | 0.81 | XIAP (0.45) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL22944442 | 0.81 | MMP2 (0.54) | MMP1MMP9MMP14XIAPBIRC3 | |
| SCHEMBL24946223 | 0.80 | MMP2 (0.41) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL1273086 | 0.80 | MMP2 (0.41) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL22303144 | 0.80 | MMP2 (0.41) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL8706642 | 0.80 | MMP2 (0.41) | MMP1MMP9MMP14MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-2240506-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1836201-B1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH INC (US) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MMP1 4778/4885MMP9 4453/4885MMP14 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.